

Flublok[®] QUADRIVALENT Influenza Vaccine

**PROVEN IN A RANDOMIZED CONTROLLED TRIAL TO
PREVENT MORE CASES OF INFLUENZA IN ADULTS 50+**
Compared with Standard-Dose, Quadrivalent Inactivated Influenza Vaccine^{1,2}

PRIMARY ENDPOINT

30% **BETTER PROTECTION
FROM INFLUENZA**
due to any PCR^a-confirmed strain^{1,2}

(95% CI: 10-47)

Primary Endpoint Definition:

PCR-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype.^{1,2}

SECONDARY ENDPOINT

43% **BETTER PROTECTION
FROM INFLUENZA**
due to any culture-confirmed strain^{1,2}

(95% CI: 21-59)

Secondary Endpoint Definition:

Culture-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype.^{1,2}

^a PCR = Polymerase chain reaction.

SAFETY IN ADULTS 50+

- **Comparable safety profile** to a standard-dose quadrivalent inactivated influenza vaccine¹
- In this randomized controlled trial, the most common local and systemic adverse reactions to **Flublok Quadrivalent vaccine** include pain at the injection site, headache, and fatigue¹

AN INFLUENZA VACCINE WITH A UNIQUE COMPOSITION



3X the amount of hemagglutinin (HA) antigen versus a standard-dose quadrivalent inactivated influenza vaccine¹



Made with recombinant DNA technology²:

- Eliminates the need to grow influenza virus
- Ensures HA antigen won't experience adaptations or mutations that could lead to reduced vaccine effectiveness

Flublok Quadrivalent is a vaccine **indicated** for active immunization against disease caused by influenza A subtype viruses and influenza type B viruses contained in the vaccine. Flublok Quadrivalent is approved for use in persons 18 years of age and older.

SELECT SAFETY INFORMATION

Flublok Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or after previous dose of the vaccine.

Please click to see full **Important Safety Information**.

Please click to see full **Prescribing Information** for Flublok Quadrivalent.

FOR MORE INFORMATION, VISIT SANOFIFLU.COM

IMPORTANT SAFETY INFORMATION FOR FLUBLOK® QUADRIVALENT (INFLUENZA VACCINE)

Flublok Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or after previous dose of the vaccine.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Flublok Quadrivalent should be based on careful consideration of the potential benefits and risks.

If Flublok Quadrivalent is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be lower than expected.

Vaccination with Flublok Quadrivalent may not protect all recipients.

For Flublok Quadrivalent, in adults 18 through 49 years of age, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, fatigue, myalgia, and arthralgia. In adults 50 years of age and older, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, and fatigue. Other adverse reactions may occur.

Before administering, please see full Prescribing Information for Flublok Quadrivalent.

Flublok Quadrivalent vaccine is manufactured by Protein Sciences Corporation, a Sanofi company, and distributed by Sanofi Pasteur Inc. Flublok Quadrivalent vaccine (CPT^{®b} code 90682) is a covered benefit under Medicare Part B.

^bCPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

References: 1. Flublok Quadrivalent vaccine [Prescribing Information]. Meriden, CT: Protein Sciences Corporation. 2. Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. *N Engl J Med.* 2017;376:2427-2436.

Flublok[®]
QUADRIVALENT
Influenza Vaccine